Developed by Boston Pharmaceuticals, efimosfermin is a fibroblast growth factor 21 (FGF21) analog currently in midstage clinical trials for steatotic liver disease, including metabolic dysfunction ...

GSK is also set to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2B in cash. "GSK's healthy dividend yield and the company's long history of payouts are ...

Another item that might prove this to be true would GlaxoSmithKline acquiring a phase 3 ready FGF21 analogue drug asset from Boston Pharmaceuticals known as efimosfermin. As I stated above ...

Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a ...

Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with ...

Biotechnology Innovation Organization trade show is expected to bring about 20,000 participants to Boston starting on Monday.

MASH Companies are Boehringer Ingelheim, Hepagene, Eli Lilly and Company, Hepion Pharmaceuticals, Ionis Pharmaceuticals, Galectin Therapeutics, Novo Nordisk A/S, Merck & Co., Zealand Pharma, Hanmi ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

The pavilion, run by the Korea Trade-Investment Promotion Agency (KOTRA), features 58 companies in cooperation with five ...

Just yesterday, GSK disclosed it was acquiring Boston Pharmaceuticals’ FGF21 analogue efimosfermin for $2bn, with plans to combine it with its in-house siRNA candidate GSK’990 to address more ...